Cellectis S.A./€ALCLS
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Cellectis S.A.
Cellectis S.A. is a biotechnology company specializing in gene-editing for cancer immunotherapy. It focuses on developing allogeneic CAR-T cell products designed to address various hematological and solid tumors using its proprietary TALEN gene editing technology. Founded in 1999, Cellectis is headquartered in Paris, France, and operates facilities in both France and the United States, enhancing its global research and development capabilities. The company's strategic positioning is characterized by its focus on creating off-the-shelf CAR-T therapies, aiming to reduce the complexity and cost associated with personalized CAR-T treatments, thereby broadening accessibility to advanced cancer therapies.
Ticker
€ALCLS
Sector
Primary listing
PAR
Employees
227
Headquarters
Website
Cellectis S.A. Metrics
BasicAdvanced
€178m
-
-€0.59
2.72
-
Price and volume
Market cap
€178m
Beta
2.72
52-week high
€4.84
52-week low
€1.25
Average daily volume
67k
Financial strength
Current ratio
1.521
Quick ratio
1.491
Long term debt to equity
122.525
Total debt to equity
137.408
Interest coverage (TTM)
-5.42%
Profitability
EBITDA (TTM)
-28.763
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-89.51%
Operating margin (TTM)
-58.66%
Effective tax rate (TTM)
0.56%
Revenue per employee (TTM)
€289,830
Management effectiveness
Return on assets (TTM)
-8.43%
Return on equity (TTM)
-76.34%
Valuation
Price to revenue (TTM)
3.607
Price to book
2.97
Price to tangible book (TTM)
2.98
Price to free cash flow (TTM)
-6.6
Free cash flow yield (TTM)
-15.15%
Free cash flow per share (TTM)
-0.359
Growth
Revenue change (TTM)
37.20%
Earnings per share change (TTM)
8.06%
3-year revenue growth (CAGR)
43.38%
10-year revenue growth (CAGR)
1.40%
3-year earnings per share growth (CAGR)
-32.90%
10-year earnings per share growth (CAGR)
-9.65%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
FAQs